Pacific Biosciences of California, Inc. (PACB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Pacific Biosciences of California, Inc. (PACB) is down 29.4% since the beginning of the year. At $1 per share, PACB is trading 51.6% below its 52-week high of $3. Investors who bought $1,000 worth of PACB shares 5 years ago would now be looking at an investment worth $42.

Pacific Biosciences of California, Inc. (PACB) has returned -29.41% so far this year and 3.94% over the past 12 months. Over the last ten years, PACB has returned -16.62% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Oct 27, 2010, PACB's average daily return is +0.07%, while the average monthly return is +1.54%. At this rate, an investment would double in approximately 3.8 years.

Historically, 43% of months were positive and 57% were negative. The best month was Oct 2015 with a return of +94.0%, while the worst month was Apr 2024 at -56.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.

On a daily basis, PACB closed higher 47% of trading days. The best single day was Sep 25, 2013 with a return of +72.8%, while the worst single day was Apr 16, 2024 at -50.6%.

Pacific Biosciences of California, Inc. has an annualized alpha of -3.91%, beta of 1.69, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since October 27, 2010.

• This stock participated in 227.60% of S&P 500 Index downside but only 130.90% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PACB ranks 45 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pacific Biosciences of California, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pacific Biosciences of California, Inc. was 98.22%, occurring on May 27, 2025. The portfolio has not yet recovered.

The current Pacific Biosciences of California, Inc. drawdown is 97.42%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Pacific Biosciences of California, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Pacific Biosciences of California, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.